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Comparison of macrocyclic and acyclic chelators
for gallium-68 radiolabelling†
Maria Iris Tsionou,a Caroline E. Knapp, b Calum A. Foley,a Catherine R. Munteanu,a
Andrew Cakebread,c Cinzia Imberti, a Thomas R. Eykyn,a Jennifer D. Young,a
Brett M. Paterson,d Philip J. Blower a and Michelle T. Ma *a
Gallium-68 (68Ga) is a positron-emitting isotope used for clinical PET imaging of peptide receptor expression.
68Ga radiopharmaceuticals used in molecular PET imaging consist of disease-targeting biomolecules tethered
to chelators that complex 68Ga3+. Ideally, the chelator will rapidly, quantitatively and stably coordinate 68Ga3+
at room temperature, near neutral pH and low chelator concentration, allowing for simple routine
radiopharmaceutical formulation. Identiﬁcation of chelators that fulﬁl these requirements will facilitate
development of kit-based 68Ga radiopharmaceuticals. Herein the reaction of a range of widely used
macrocyclic and acyclic chelators with 68Ga3+ is reported. Radiochemical yields have been measured under
conditions of varying chelator concentrations, pH (3.5 and 6.5) and temperature (25 and 90 C). These
chelators are: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-1,4,7-
triacetic acid (NOTA), 1,4,7-triazacyclononane macrocycles substituted with phosphonic (NOTP) and
phosphinic (TRAP) groups at the amine, bis(2-hydroxybenzyl)ethylenediaminediacetic acid (HBED),
a tris(hydroxypyridinone) containing three 1,6-dimethyl-3-hydroxypyridin-4-one groups (THP) and the
hexadentate tris(hydroxamate) siderophore desferrioxamine-B (DFO). Competition studies have also been
undertaken to assess relative complexation eﬃciencies of each chelator for 68Ga3+ under diﬀerent pH and
temperature conditions. Performing radiolabelling reactions at pH 6.5, 25 C and 5–50 mM chelator
concentration resulted in near quantitative radiochemical yields for all chelators, except DOTA. Radiochemical
yields either decreased or were not substantially improved when the reactions were undertaken at lower pH
or at higher temperature, except in the case of DOTA. THP and DFO were the most eﬀective 68Ga3+
chelators at near-neutral pH and 25 C, rapidly providing near-quantitative radiochemical yields at very low
chelator concentrations. NOTP and HBED were only slightly less eﬀective under these conditions. In
competition studies with all other chelators, THP demonstrated highest reactivity for 68Ga3+ complexation
under all conditions. These data point to THP possessing ideal properties for rapid, one-step kit-based
syntheses of 68Ga-biomolecules for molecular PET imaging. LC-MS and 1H, 13C{1H} and 71Ga NMR studies of
HBED complexes of Ga3+ showed that under the analytical conditions employed in this study, multiple
HBED-bound Ga complexes exist. X-ray diﬀraction data indicated that crystals isolated from these solutions
contained octahedral [Ga(HBED)(H2O)], with HBED coordinated in a pentadentate N2O3 mode, with only one
phenolic group coordinated to Ga3+, and the remaining coordination site occupied by a water molecule.
Introduction
Gallium-68 (68Ga) is a positron-emitting isotope with emission
properties (t1/2 ¼ 68 min, b+ 90%, Emax ¼ 1880 keV) that make it
suitable for diagnostic imaging with positron emission tomog-
raphy (PET). A pharmaceutical grade 68Ge/68Ga generator has
recently become commercially available,1 providing hospitals
with on-site access to a GMP-grade diagnostic PET radionuclide
without the need for local cyclotron facilities. The most widely
utilised 68Ga radiopharmaceuticals consist of 68Ga coordinated
to a chelator that is attached to a peptide for targeting cell-
surface receptors of tumours. Numerous centres already
routinely produce diagnostic 68Ga–HBED–PSMA2,3 and 68Ga–
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DOTA–TATE4–6 for whole-body PET imaging of prostate and
neuroendocrine cancers respectively. These radiotracers have
had a signicant impact on patient management in centres
where they are available, but the complexity of their radiosyn-
thesis in hospitals is a barrier to widespread implementation.
Radiosynthesis of 68Ga–DOTA–TATE requires heating at 80–
100 C in order for the DOTA chelator to chelate radiophar-
maceutical concentrations of 68Ga3+ with yields greater than
80%.7–9 On the other hand, 68Ga–HBED–PSMA can be prepared
at ambient temperatures, but HBED forms multiple species
when complexed to Ga3+.10 This is undesirable as it is possible
that the diﬀerent species have diﬀerent pharmacological
proles. Heating is employed to increase formation of the most
thermodynamically favoured compound, although the structure
of this complex has not been dened. Even with heating, pop-
ulations of other isomers are observed.10 The radiosyntheses of
68Ga–DOTA–TATE and 68Ga–HBED–PSMA are undertaken at pH
3–5.
As a result of heating requirements at acidic pH, clinical
radiosyntheses of both 68Ga–DOTA–TATE and 68Ga–HBED–
PSMA require multiple manipulations or complex automated
equipment.9,10 Typical 68Ga radiopharmaceutical syntheses
involve (i) elution of 68Ga from a generator, (ii) pretreatment of
eluate to remove contaminating metal impurities that interfere
with radiolabelling, as well as 68Ge “breakthrough”, (iii) addi-
tion of 68Ga to aqueous solutions of peptide–chelator precursor
at pH 3–5, (iv) heating for 5–10 min (followed by cooling) (v)
removal of unreacted 68Ga and buﬀering salts (using solid
phase extraction cartridges) and (vi) reconstitution in physio-
logically compatible solutions for patient administration. In
centres that are equipped for more complex preparations of 18F
radiopharmaceuticals, this is not a barrier to routine radio-
synthesis but it is time-consuming and costly. However, in
regional healthcare centres, or hospitals in countries with
developing healthcare systems, such complexity will be a barrier
to widespread implementation.
Chelators that quantitatively coordinate 68Ga3+ at near-
neutral pH, room temperature and low concentrations of
chelator-bioconjugate will enable one-step, kit-based radio-
labelling protocols, with concomitant widespread patient
benet. Such radiosyntheses would ideally only require a kit vial
containing bioconjugate and buﬀer components, 68Ga gener-
ator eluate, a syringe and appropriate radiation shielding.
Chelators that full these requirements would also be useful for
radiolabelling of small proteins that are susceptible to unfold-
ing or degradation at extremes of pH and temperature. Over the
past decade, several chelators have been evaluated and/or
developed for 68Ga radiolabelling of biomolecules, to over-
come the limitations of DOTA (1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid). These include chelators based on
1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA and its
derivative NODAGA),11–15 1,4,7-triazacyclononane (tacn) macro-
cycles substituted with phosphonic (NOTP16,17) and phosphinic
(TRAP18,19) groups at the amine, hexaazamacrobicycles,20 a pyr-
idyl-substituted DOTA macrocycle (PCTA),15,21 bis(2-
hydroxybenzyl)ethylenediaminediacetic acid (HBED) and
related compounds possessing phenol, amine and carboxyl
donor groups,3,22 6-amino-1,4-diazepanes with acetate substit-
uents at the amines (DATA),23–26 a siderophore-derived macro-
cyclic chelator with hydroxamate groups (FSC),27 the acyclic
siderophore desferrioxamine-B (which also contains hydrox-
amates),28,29 and an acyclic chelator based on a substituted
pyridine carboxylate with an N4O2 binding mode (DEDPA)
(Chart 1).30–32 Our research group has recently developed
tris(hydroxypyridinone) (THP) derivatives based on 1,6-
dimethyl-3-hydroxypyridin-4-one units.33–39 Of these chelators,
NOTA/NODAGA, TRAP/NOPO, HBED, FSC, DATA, DFO, DEDPA
and THP can reportedly be radiolabelled with 68Ga3+ at ambient
temperature. Only DATA derivatives24 and THP deriva-
tives33–35,37,38 have been reported to complex 68Ga3+ above pH 5 at
ambient temperature. Many of these ligands provide highly
rigid and inert Ga3+–chelator complexes. Rigidity is imparted by
both selection of appropriate “hard” donor atoms with high
aﬃnity for Ga3+, which has a relatively high charge density, and
the geometry or topology of the chelator itself. Chelators with
pre-arranged conformations18,26,32 that accommodate octahe-
dral binding of Ga3+ favour very high complex rigidity,
contributing to kinetic stability of the resulting Ga3+ complex.
Most radiosyntheses of 68Ga–chelator complexes have been
undertaken in acidic solution, below pH 5. This is because
hydrated Ga3+ species such as [Ga(H2O)6]
3+ predominate in
solution below pH 4 but as the pH is raised above 4, the poorly
soluble hydroxide species Ga(OH)3 is formed, until the pH
exceeds 6.3, where tetracoordinate [Ga(OH)4]
 predomi-
nates,40–43 although this is strongly dependant on temperature
and is inuenced by concentrations of other metal ions and
coordinating molecules in solution.44,45 For eﬃcient 68Ga3+
radiolabelling of chelate–peptide conjugates above pH 4,
chelate complex formation must eﬀectively compete with 68Ga-
colloid formation. Preferably, the rate of chelation will be
diﬀusion-controlled, so that complex formation outcompetes
68Ga3+ colloid formation. The amounts of 68Ga eluted from
clinical generators are in the range of 400–2000 MBq, approxi-
mately equivalent to 4–20 pmol of 68Ga3+ in 1–5 mL of solution,
i.e. nanomolar concentrations. Highly eﬃcient chelators are
required to quantitatively coordinate such low concentrations
of metal ion without excessively high chelator concentrations.
For most of the chelators mentioned above, their Ga3+
complexes and their complexes with some other metal ions,
metal stability constants and protonation constants have been
reported (Table 1). These data are very useful in predicting the
ability of a chelator to coordinate Ga3+, the selectivity of
a chelator for Ga3+ over other metal ions, and the ability of other
ligands such as hydroxide ions, to compete for Ga3+ binding
under physiological conditions. These data do not, however,
predict the kinetics of complexation, and without very detailed
speciation studies, they do not describe the complexity of the
reaction matrix in 68Ga radiolabelling solutions where other
adventitious metal ions are present, as well as buﬀer
components.
To the best of our knowledge, there have been no compre-
hensive side-by-side comparisons of Ga3+ chelators to evaluate
relative radiolabelling eﬃciencies. Several prior studies have
compared 68Ga radiolabelling for a limited number of
This journal is © The Royal Society of Chemistry 2017 RSC Adv., 2017, 7, 49586–49599 | 49587
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chelators.16,21,24,33,35,46,47 Some of these studies have compared
diﬀerent chelator concentrations or amounts, and all of these
studies only explore one or two specic reaction conditions. In
some of these studies including our own, the 68Ga radio-
labelling conditions used for each chelator are not iden-
tical.33,35,46 Therefore, to identify the most suitable chelators to
take forward for kit-based 68Ga radiolabelling, we have
compared the eﬃciency of 68Ga radiolabelling of commercially
available DOTA, NOTA, NOTP, TRAP, HBED, THP and DFO,
under four diﬀerent reaction conditions (high and ambient
temperatures, and neutral and low pH conditions), and across
ve orders of magnitude of chelator concentration (50 nM to




All solvents and reagents were obtained from Sigma-Aldrich
(Dorset, UK) unless otherwise indicated. DOTA, NOTA and
NOTP were purchased from Macrocyclics (Dallas, USA). TRAP
was purchased from CheMatech (Dijon, France). HBED was
Chart 1
Table 1 Proton and Ga3+ aﬃnity constants of chelators used in this
study
Chelator log Ka log K1
DOTA48,49 11.74, 9.76, 4.68, 4.11, 2.37 26.05
NOTA18,50 13.17, 5.74, 3.22, 1.96 29.63
NOTP51 11.7, 9.1, 7.5, 5.8, 3.1, 0.9 —
TRAP19 11.48, 5.44, 4.84, 4.23, 3.45, 1.66 26.24
HBED52 12.60, 11.00, 8.44, 4.72, 2.53, 1.74 39.57
DFO53 10.79, 9.55, 8.96, 8.32 28.65
Deferipronea,54,55 9.86, 3.70;54 9.78, 3.61 55 (log b3) 38.42;
54
37.35 55
a In the absence of published stability constants for THP, we have
included log b3 values for the related [Ga(deferiprone)3] complex
(deferiprone ¼ 1,2-dimethyl-3-hydroxypyridin-4-one).
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purchased from Santa Cruz Biotechnology (Dallas, USA). DFO
was purchased from Sigma-Aldrich. THP was synthesised in our
laboratory according to a previously reported procedure.33,56 The
purchased chemicals were used without further purication.
NMR spectra were acquired on Bruker Avance 400 MHz spec-
trometers (either narrow-bore or wide-bore) (Bruker, Germany)
equipped with either a 5 mm QNP probe or a 5 mm BBO probe
at 298 K. Spectra were referenced to residual solvent signals or
TMS. High-performance liquid chromatography (HPLC) anal-
ysis was carried out using an Agilent 1200 LC systemwith in-line
UV and gamma detection (Flow-Count, LabLogic). Instant thin
layer chromatography plates (iTLC-SG) were obtained from
Agilent Technologies (California, USA) and iTLC strips were
visualized and quantied using a Cyclone Plus Storage Phos-
phor System (Perkin Elmer) interfaced with OptiQuant V5.0
soware (Perkin Elmer). Analytical reverse phase HPLC were
acquired using an Agilent Eclipse XDB-C18 column (9.4  250
mm, 5 mm) and UV spectroscopic detection at 220 nm. Aliquots
(50 mL) of each radiolabelled sample were injected onto the
column, using a ow rate of 1 mL min1, and the following
gradient: 0–5 min: 100% A/0% B; 5–25 min: 100% A/0% B to
60% A/40% B. Mobile phase A comprised water with 0.1% tri-
uoroacetic acid and mobile phase B comprised acetonitrile
with 0.1% triuoroacetic acid. Analytical LC-MS were recorded
in the positive ion mode on an Agilent 6510 Q-TOF LC/MS mass
spectrometer coupled to an Agilent 1200 LC system (Agilent,
Palo Alto, CA) and a LabLogic scintillation detector Flow-count
system (Sheﬃeld, UK). An Agilent Eclipse XDB-C18 column (9.4
 250mm, 5 mm) and UV spectroscopic detection at 220 nmwas
used with a ow rate of 1 mLmin1, and the following gradient:
0–5 min: 100% A/0% B; 5–25 min: 100% A/0% B to 0% A/100%
B. Mobile phase A comprised water with 0.1% formic acid and
mobile phase B comprised acetonitrile with 0.1% formic acid.
Elemental analysis was performed by the Science Centre, Lon-
don Metropolitan University.
68Ga radiolabelling and iTLC quantication
68Ga was eluted from an Eckert & Ziegler 68Ge/68Ga generator
system (Berlin, Germany). Aqueous HCl solution (0.1 M, 5 mL)
was passed through the generator and the eluate was collected
in 5  1 mL fractions. Aliquots of the second fraction (1 mL,
containing 130–230 MBq 68Ga) were used directly for radio-
labelling reactions.
Chelators were dissolved in aqueous solutions of sodium
acetate (0.2 M) or ammonium acetate (0.2 M) to provide solu-
tions with chelator concentrations ranging from 50 nM to 1 mM
(50 nM, 500 nM, 5 mM, 50 mM, 500 mM, and 1 mM). Ligand
solutions were freshly prepared from stock solutions for each
experiment. 68Ga (10 mL, approx. 2 MBq in 0.1 M aqueous HCl)
was added to chelator solutions (100 mL) and the reaction
solution was incubated at either 25 or 90 C. The nal pH of the
reaction solutions was 3.5 and pH 6.5 for the sodium acetate
and ammonium acetate solutions respectively. Aer 10 min, the
reaction solution was analysed by iTLC (glass microber chro-
matography paper impregnated with silica gel, 80  10 mm).
Separately, solutions of 68Ga3+ (10 mL, approx. 2 MBq in 0.1 M
aqueous HCl) were added to aqueous solutions of sodium
acetate (0.2 M) or ammonium acetate (0.2 M), and incubated at
either 25 or 90 C. Aer 10 min, the solutions were analysed by
iTLC.
Three diﬀerent mobile phases were employed for iTLC:
(1) For THP, DFO and chelator-free reactions under all
reaction conditions, aqueous sodium citrate solution (0.1 M, pH
5.5) was used. [68Ga(chelator)] Rf < 0.1; non-chelated, soluble
68Ga3+ Rf > 0.9;
68Ga colloids: <0.1. Based on quantication of
68Ga colloid and soluble 68Ga3+ in chelator-free reactions, RCY
values were adjusted to account for coincident Rf values of
68Ga
colloid, [68Ga(THP)] and [68Ga(DFO)].
(2) For NOTP under all reaction conditions, and DOTA,
NOTA, TRAP and HBED, under all conditions except pH 3.5,
90 C, aqueous sodium phosphate solution (0.4 M, pH 4) was
used. [68Ga(NOTP)] Rf¼ 0.6–0.7; DOTA, NOTA, TRAP andHBED:
[68Ga(chelator)] Rf ¼ 0.8–1; non-chelated 68Ga3+ Rf < 0.1.
(3) For DOTA, NOTA, TRAP andHBED at pH 3.5 and 90 C, an
ammonium acetate solution (1 M in 80%methanol, 20% water)
was used. [68Ga(DOTA)] Rf ¼ 0.65–0.75; [68Ga(NOTA)] Rf ¼ 0.8–
0.9; [68Ga(HBED)] Rf ¼ 0.9–1; [68Ga(TRAP)] Rf ¼ 0.4–0.6; non-
chelated 68Ga3+ Rf ¼ <0.3. These conditions were selected
because aer heating 68Ga solutions at pH 3.5 and 90 C, two
distinct compounds were observed for non-chelated 68Ga3+: Rf¼
0–0.1 and 0.7–0.9 using mobile phase (2). Thus, non-chelated
68Ga3+ could not be distinguished from [68Ga(chelator)] using
mobile phase (2) aer heating at pH 3.5 and 90 C (except in the
case of [68Ga(NOTP)]).
iTLC conditions and Rf values are also summarised in Tables
S3–S6.†
iTLC plates were imaged and quantied by digital autora-
diography using instruments and soware described above.
ICP-MS analysis of 68Ga generator eluate
Fractionated eluate (as described above) was allowed to decay
for several days before it was analysed by ICP-MS. The quanti-
cation of metal contaminants was carried out on a Perki-
nElmer NexION 350D Inductively coupled plasma mass
spectrometer (ICP-MS) running Syngistix v1.0 soware with
a CETAC ASX520 autosampler (King's College London, UK). The
acquisition mode included 5 replicates averaged to give re-
ported values (Fig. 2, S12 and S13†) for 27Al, 59Co, 52Cr, 65Cu,
56Fe, 69Ga, 72Ge, 55Mn, 60Ni, 208Pb, 45Sc, 118Sn, 47Ti, 51V, 66Zn and
68Zn. The dwell time was 50 ms per isotope, with 18 L min1
main argon ow, 1.2 L min1 auxiliary argon ow, 0.97 L min1
nebuliser argon ow (optimised), 1600 W RF power, 0.2
mL min1 sample ow, and KED cell mode with 1.2 mL min1
helium ow.
HPLC analysis of [68Ga(chelator)] complexes and competition
studies
68Ga3+ generator eluate (10 mL in 0.1 M aqueous HCl, approx. 2
MBq) was added to chelator solutions (1 mM chelator, 100 mL in
either 0.2 M ammonium acetate, or 0.2 M sodium acetate) and
the reaction mixtures were incubated at either 25 C or 90 C for
This journal is © The Royal Society of Chemistry 2017 RSC Adv., 2017, 7, 49586–49599 | 49589
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10 min, aer which they were applied to an analytical reverse
phase C18 HPLC column.
For competition studies, 68Ga3+ generator eluate (20 mL in
0.1 M aqueous HCl, approx. 4 MBq) was added to a solution
containing equimolar concentrations of two chelators (each 500
mM in either 200 mL 0.2 M ammonium acetate, or 200 mL 0.2 M
sodium acetate) and the reaction mixtures were incubated at
either 25 C or 90 C for 40 min, aer which they were applied to
an analytical reverse phase C18 HPLC column. Data were pro-
cessed and analysed using Laura Radiochromatography So-
ware (LabLogic).
Preparation of [natGa(HBED)]
A sample of HBED (40 mg, 0.09 mmol) was reacted with
Ga(NO3)3$xH2O (40 mg, 0.15 mmol, 1.6 equiv.) in aqueous
ammonium acetate solution (0.2 M, 5–10 mL) and heated at
90 C for 30 min. The solution was then applied to an
Agilent Eclipse semi-preparative reverse phase XDB-C18 column
(9.4  250 mm, 5 mm) with a 3 mL min1 ow rate, and the
reaction solution was puried using a gradient elution, in which
mobile phase A consisted of water containing 0.1% TFA and
mobile phase B consisted of acetonitrile containing 0.1% TFA.
The concentration of B increased at a rate of 1% min1.
[Ga(HBED)] eluted with a retention time of 32 min. Fractions
containing pure [Ga(HBED)] were combined, lyophilised, and
1H and 13C{1H} NMR spectra (in both D2O/CD3OD (50%/50%)
and D2O/CD3CN (60%/40%)), and LC-MS chromatograms were
acquired. Data are reported in Fig. 4, 5 and S4–S8.†
Crystals of Ga–HBED of were obtained from a solution of D2O
and CD3CN. Anal. calc. for [Ga(HBED)(H2O)]$CH3CN
(C22H26GaN3O7): C, 51.39; H, 5.10; N, 8.17. Found: C, 51.23; H,
5.25; N, 8.10. A suitable crystal containing [Ga(HBED)(H2O)] was
selected and mounted on a nylon loop on a SuperNova Atlas
diﬀractometer with Cu Ka radiation (l ¼ 1.54184 A˚). The crystal
was kept at 150.4(5) K during data collection. Using Olex2,57 the
structure was solved with the ShelXS58 structure solution
program using Direct Methods, and rened with the ShelXL59
renement package using Least Squares minimisation.
Crystal structure determination
Crystal data for [Ga(HBED)(H2O)]$CH3CN (C22H26GaN3O7)
(M ¼ 514.18 g mol1): monoclinic, space group P21/c (no. 14),
a ¼ 12.96001(14) A˚, b ¼ 7.01939(10) A˚, c ¼ 25.0910(3) A˚,
b ¼ 97.7700(10), V ¼ 2261.60(5) A˚3, Z ¼ 4, T ¼ 150.4(5) K,
m(CuKa) ¼ 2.093 mm1, Dcalc ¼ 1.510 g cm3, 34 357 reections
measured (6.884 # 2Q# 147.354), 4541 unique (Rint¼ 0.0461,
Rsigma¼ 0.0263) which were used in all calculations. The nal R1
was 0.0292 (I > 2s(I)) and wR2 was 0.0747 (all data). The iden-
tication code is xstr0762. Deposit number for [Ga(HBED)-
(H2O)]$CH3CN: CCDC 1564603.†
Results
A comprehensive selection of chelators was reacted with
generator-produced solutions of 68Ga3+ at a range of chelator
concentrations, at high (90 C) and room (25 C) temperatures,
and in acidic (pH 3.5) and near neutral (pH 6.5) aqueous acetate
solutions. In all cases, the reaction time was 10 min. The
chelators are: macrocyclic DOTA, NOTA, NOTP and TRAP, and
acyclic HBED, DFO and THP (Chart 1). [Note: for ease of
nomenclature, charge and protonation states are not included
in these abbreviations of the ligands or complexes.]
Quantifying the eﬃciency of 68Ga3+ chelation
Whilst many ligands will chelate a metal quantitatively if the
concentration is high enough, only the most eﬃcient will
continue to do so as the concentration is reduced.12,21,36,46,60,61 A
series of reactions was undertaken in which a solution of
generator-produced 68Ga3+ (approx. 2 MBq in 0.1 M aqueous
HCl, 10 mL) was added to a solution of chelator at a concentra-
tion in the range 500 mM to 50 nM (100 mL). The nal pH of the
reaction solution was 3.5 (using 0.2 M sodium acetate) or 6.5
(using 0.2 M ammonium acetate). Aer 10 min reaction time,
radiochemical yields (RCY) were measured using instant thin
layer chromatography (iTLC). Experimental data are supplied
for each chelator in Fig. 1, S1, S2† and Table 2. A summary of
iTLC conditions is provided in Tables S3–S6.†
Room temperature radiolabelling. At pH 3.5, 25 C, and
a chelator concentration of 50 mM, RCYs were greater than 85%
for all chelators except DFO (Fig. 1, S1, S2† and Table 2). At 5 mM
and 50 mM chelator concentrations, the best performing
chelators (i.e. that demonstrated highest labelling eﬃciency)
were NOTA and TRAP. At concentrations of 50 mM, RCY of
[68Ga(NOTA)] was 97  1.7%, and RCY of [68Ga(TRAP)] was 95 
1.3%. At 5 mM, RCY of [68Ga(NOTA)] was 93  2.0%, and RCY of
[68Ga(TRAP)] was 92  2.4%.
At pH 6.5, 25 C, and a chelator concentration of 5 mM, RCYs
were greater than 85% for all chelators except for DOTA. At pH
6.5 and 25 C, at very low chelator concentrations of 500 nM and
5 mM, the best performing chelators were DFO and THP. At
concentrations of 5 mM, RCY of [68Ga(DFO)] was 97  1.0%, and
RCY of [68Ga(THP)] was 97  0.1%. At 500 nM, RCY
of [68Ga(DFO)] was 96  1.5% and the RCY of [68Ga(THP)] was
97  0.6%.
The pKa values for deprotonation of coordinating O donor
atoms of NOTA and TRAP are substantially lower than those of
DFO and THP (Table 1). At pH 3.5, both NOTA and TRAP
complexed 68Ga3+ with eﬃciency comparable to that achieved at
pH 6.5. At pH 3.5, at concentrations below 500 mM, RCYs of THP
and DFO with 68Ga3+ were relatively poor, however with an
increase in pH, Ga3+ competed more eﬀectively with protons for
coordination to THP and DFO at lower concentrations of
chelator. Thus, at pH 6.5, the lowest concentration at which
a RCY greater than 95% was reached was 500 nM, achieved
using DFO and THP.
High temperature radiolabelling. For some macrocycles, the
energies of activation for chelation of metal ions are signi-
cantly higher than those of linear chelators. To overcome these
substantial kinetic barriers when radiolabelling DOTA conju-
gates with 68Ga3+, reaction solutions are heated. On the other
hand, studies have demonstrated that radioisotopes of Ga3+
bind to NOTA and its derivatives at room temperature12,15 – the
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kinetic barriers to Ga3+ complexation are likely lower for NOTA
than DOTA.11,49 To evaluate the contribution of kinetics to
radiolabelling eﬃciencies at room temperature, radiolabelling
reactions (at chelator concentrations of 50 mM to 50 nM) were
also undertaken at 90 C for all chelators except DFO (Fig. 1, S1,
S2† and Table 2). HPLC studies (described below) suggested
that either DFO or its Ga3+ complex decompose at 90 C.
At pH 3.5, 90 C, and a chelator concentration of 50 mM,
RCYs were greater than 85% for all chelators except NOTP, and
the most eﬃcient chelators were THP, DOTA and TRAP. RCY of
[68Ga(THP)] was 96 0.5%, RCY of [68Ga(DOTA)] was 95 0.9%
and RCY of [68Ga(TRAP)] was 93  0.6%. At 5 mM, RCY of
[68Ga(THP)] was 93 1.1%, RCY of [68Ga(DOTA)] was 90 1.5%
and RCY of [68Ga(TRAP)] was 92  1.5%. Thus, at pH 3.5,
heating substantially improves RCY at chelator concentrations
of 500 nM to 5 mM for DOTA and THP. The increased RCY
observed for [68Ga(DOTA)] at 5 mM at 90 C (90  1.5%)
compared to 25 C (21  5.6%) is consistent with previous
reports.8,9,19 This suggests that the labelling eﬃciencies of these
ligands at pH 3.5 at room temperature are limited by kinetic
barriers.
Interestingly, the RCY (57  2.6%) of [68Ga(NOTA)] at 5 mM,
90 C, pH 3.5 was substantially decreased compared to that
observed at 25 C (93  2.0%). It is possible that contaminating
metal ions present in generator eluate (see below) eﬀectively
compete with Ga3+ for NOTA binding at high temperature, but
that at lower temperature, the kinetic barriers to complexation
of these other metal ions prevent them from competing with
Ga3+.
At pH 6.5, 90 C, and a chelator concentration of 5 mM, RCYs
were greater than 94% for all chelators except DOTA. In contrast
to results observed at room temperature, the best performing
chelators were NOTP and HBED. At a chelator concentration of
500 nM, RCY of [68Ga(NOTP)] was 94  0.8% and RCY of
[68Ga(HBED)] was 88  4.4%.
The RCY of [68Ga(THP)] at 500 nM and pH 6.5 was
substantially reduced at 90 C (11  2.6%) compared to RCY at
25 C (97  0.6%). Again, it is possible that THP complexes of
metal ion contaminants are formed at high temperature, but
not low temperature.
68Ga generator ICP-MS eluate analysis. Diﬀerent batches of
68Ga eluate were used for all of the above experiments. Prior
work has shown that the concentrations of contaminating
metal ions increase with increasing time between 68Ga
generator elutions.9,62 In our experiments, the time between
elutions was 2–24 hours. To better characterise these reaction
solutions, and identify metal ions that compete with 68Ga3+
for chelator complexation, the concentration of selected
metals ions in two batches of generator eluate was quantied,
with each eluate fractionated into ve samples (each 1 mL).
Eluates from two separate elutions were assessed: elution A
was obtained 5 hours aer the previous elution, and elution B,
150 hours (ve days) aer the previous elution. The concen-
trations of Al, Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn (natZn and
68Zn), Ga, Ge, Sn and Pb in generator eluate solution and the
hydrochloric acid solution used as eluate were quantied
using ICP-MS.
In most eluate fractions, including the second fraction used
for radiolabelling, Al, Ti, Fe, Zn, Ga and Pb were present at
concentrations of 0.1 mM to 5 mM (Fig. 2, S12 and S13†).
Concentrations of 68Zn (arising from decay of 68Ga) were
signicantly higher in eluate B than eluate A. This is expected:
eluate B contained decay products of 150 h of 68Ge/68Ga decay,
whereas eluate A contained decay products of only 5 h of
68Ge/68Ga decay. Concentrations of natGa were also higher in
eluate B compared to eluate A. Although the sampling size here
Fig. 1 Radiochemical yields for the reaction of 68Ga3+ with DOTA, NOTA, NOTP, TRAP, HBED, DFO and THP under diﬀerent concentrations of
chelator (500 mM to 50 nM); diﬀerent pH conditions (pH 3.5 or pH 6.5); and diﬀerent temperatures (25 C or 90 C), after 10 min reaction.
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is very low, the measured metal contaminant levels fall within
a similar range to that of prior reports.9 The source of these
metal ion contaminants includes the HCl solution used as eluate
(contributing a proportion of measured Al, Fe, Zn and Pb), and
components of the 68Ga generator including titanium dioxide on
a borosilicate glass column, lead shielding and tubing.
Table 2 Radiochemical yields (standard deviation) for the reactions of 68Ga3+ with DOTA, NOTA, NOTP, TRAP, HBED, DFO and THP.
Experiments were undertaken in triplicate
Chelator Concentration (mM) pH 3.5, 25 C pH 3.5, 90 C pH 6.5, 25 C pH 6.5, 90 C
DOTA 500 98.3  0.4 97.0  0.7
50 86.7  5.0 95.3  0.9 73.2  6.4 97.2  0.3
5 20.7  5.6 90.1  1.5 9.6  5.9 21.6  2.5
0.5 6.2  2.8 16.5  2.2 2.3  0.7 2.8  0.2
0.05 3.5  1.1 3.1  0.7 1.7  0.5 2.8  0.5
NOTA 500 98.2  0.6 96.6  1.2
50 96.2  1.7 93.7  0.3 97.5  0.1 98.5  0.1
5 93.2  2.0 57.3  2.6 90.6  4.5 94.4  0.4
0.5 25.4  35.6 17.4  2.1 3.8  0.3 4.9  0.4
0.05 4.0  2.2 2.2  0.5 1.9  0.7 2.8  0.2
NOTP 500 97.0  0.8 96.7  1.8
50 95.0  1.8 54.3  2.4 97.5  0.1 97.3  0.4
5 68.7  25.0 74.9  3.4 96.6  0.4 94.2  0.9
0.5 26.8  33.0 20.0  1.9 84.3  0.9 93.5  0.8
0.05 5.2  3.7 3.9  0.7 4.8  0.4 6.8  1.2
TRAP 500 95.6  0.7 96.5  0.4
50 95.0  1.3 93.0  0.6 96.6  0.1 96.0  1.4
5 92.5  2.4 92.0  1.5 89.0  1.4 95.2  0.4
0.5 23.0  9.5 53.1  4.8 5.1  0.8 8.8  2.0
0.05 7.4  1.5 5.5  0.6 2.0  0.5 2.8  0.5
HBED 500 93.2  3.8 92.2  0.6
50 90.4  8.1 87.7  0.5 93.3  3.0 97.2  0.4
5 68.6  23.5 75.2  0.8 92.7  2.2 95.4  0.8
0.5 11.6  11.9 5.8  0.4 86.0  3.9 87.5  4.4
0.05 4.9  2.2 2.5  0.4 4.6  0.7 5.1  0.8
DFO 500 96.0  0.8 96.4  1.4
50 24.5  1.9 97.5  0.7
5 23.0  12.9 97.0  1.0
0.5 10.5  5.4 95.8  1.5
0.05 11.2  5.0 3.6  1.3
THP 500 96.7  1.4 96.2  0.8 95.8  1.6 94.3  0.7
50 92.7  4.2 95.9  0.5 97.1  1.1 94.2  0.6
5 77.8  13.5 92.7  1.1 97.1  0.1 94.0  0.3
0.5 25.4  6.8 83.4  1.1 97.1  0.6 10.7  2.6
0.05 14.0  6.8 24.3  3.4 3.8  3.6 6.1  1.1
Fig. 2 The concentrations of selected metals in 68Ga generator eluate from the second 1 mL fraction (measured by ICP-MS). Elution A was
obtained 5 hours after the previous elution, and elution B, 150 hours (ﬁve days) after the previous elution. Error bars represent standard deviation
of the measurement (n ¼ 5). 68Zn concentrations correspond to 68Zn arising from 68Ga decay.
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Complexes of Al3+, Ti4+, Fe3+, Zn2+, Ga3+ and Pb2+ with many
of these chelators or their derivatives have been described and
characterised. Some of these chelators (for example, HBED,52
hydroxypyridinones,63 NOTA18 and TRAP18,19) have demon-
strated selectivity for Ga3+ over divalent ions. However, it is
likely that the presence of Al3+, Fe3+ and natGa3+, and the high
concentrations of Ti4+, Zn2+ and Pb2+, will decrease RCY of the
desired 68Ga–chelator complex for all chelators used in these
experiments. It is also likely that diﬀerences in metal concen-
trations in diﬀerent eluates leads to variability in RCYs.
HPLC radiochromatograms of 68Ga complexes
Before performing 68Ga competition experiments with reverse-
phase HPLC, each chelator was reacted with 68Ga3+ solution,
and HPLC radiochromatograms (Fig. S3†) were acquired to
determine the retention times and chromatographic behaviour
of each complex. For [68Ga(DFO)] at 90 C, multiple signals were
observed in the radiochromatograms at both pH 3.5 and 6.5,
with wide-ranging retention times. We did not pursue further
experiments to elucidate the nature of these species, nor did we
study any further reactions of DFO at 90 C. Others have
previously described the structure of [Ga(DFO)].64 We postulate
that the ligand or complex are not stable at 90 C, and that the
signals correspond to decomposition products.
Ga–HBED complexes
Prior studies have reported that derivatives of the HBED
chelator form isomers when complexed to Ga3+ in solution,10,65
and we have previously suggested that these correspond to
geometric isomers (Fig. 3),66 however little empirical evidence is
available to support this. Consistent with all previous reports of
Ga3+-bound HBED (Ga–HBED) derivatives, multiple species
with distinct HPLC retention times were formed (Fig. 4). At
25 C, at least three distinct signals in the radiochromatogram
of 68Ga3+–HBED could be distinguished but at 90 C, only two of
these signals were observed (Fig. S4†). The distribution of these
species at each temperature was the same whether they were
synthesised at pH 3.5 or 6.5.
To further characterise these reaction products, a solution of
HBED was reacted with 1.6 equivalents Ga(NO3)3 at 90 C, and
the resulting complex was isolated (using semi-preparative
reverse phase C18 HPLC as a mixture of species, including
stereo- and possible geometric-isomers). The isolated material
was characterised by NMR and LC-MS.
The LC-MS retention times (absorbance at l ¼ 220 nm and
total ion count) were coincident with HPLC signals observed
from reaction solutions of 68Ga3+ with HBED at 90 C (Fig. 4).
The product was resolved into two distinct molecular ions by
LC-MS, with both corresponding to the expected isotopic
pattern for {[Ga(HBED)] + 2H+} (Fig. 4c inset). In the 13C{1H}
spectrum of Ga–HBED, there are four signals corresponding to
C]O groups, four signals corresponding to C–O phenolic
groups and ten signals (rather than the expected twelve) corre-
sponding to methylene groups. Presumably there are two pairs
of coincident signals in the case of the methylene groups. In the
1H NMR spectra (including COSY and heteronuclear HSQC
1H–13C spectra, Fig. S5–S8†), the chemically distinct methylene
protons display geminal coupling, and the spectra are also
consistent with formation of multiple species. 13C{1H} and 1H
spectra were acquired in a mixture of D2O/CD3CN (60%/40%),
and separately, in a mixture of D2O/CD3OD (50%/50%). Similar
spectra were observed for both samples, with no notable
diﬀerences in the number of signals, nor their chemical shis
and relative intensities. In the 71Ga spectrum (acquired in D2O/
CD3CN), a very broad signal is observed, likely arising from
overlaid broad resonances corresponding to diﬀerent Ga–HBED
complexes (Fig. 4). A small amount of unchelated Ga3+,
presumably [Ga(H2O)6]
3+, is also present. The broad signal from
71Ga reects the asymmetric environment in all Ga3+–HBED
species, causing signicant quadrupolar relaxation, compared
to the symmetric aqua ion.
1H, 13C{1H}, COSY, HSQC and 71Ga NMR spectra (Fig. 5 and
S5–S8†) are consistent with formation of at least two diﬀerent
species. We postulate that these species could include the three
possible geometric isomers of a hexadentate N2O4 species
(Fig. 3), as well as complexes in which the HBED ligand coor-
dinates to Ga3+ with lower density, (with each species consisting
of NMR-indistinguishable D and L enantiomers). For each of
the geometric isomers designated [Ga(HBED)]-1 and
[Ga(HBED)]-2, there are three chemically distinct methylene
environments, one phenolic environment and one carboxylate
environment. For the geometric isomer designated [Ga(HBED)]-
3, there are six chemically distinct methylene environments,
two phenolic environments and two carboxylate environments.
For a Ga–HBED pentadentate species (with a monodentate
ligand occupying the sixth coordination site), there are six
chemically distinct methylene environments, two phenolic
environments and two carboxylate environments.
Fig. 3 Possible geometric isomers for hexadentate [Ga(HBED)]. Note that each isomer depicted here is one of a pair of enantiomers.
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Slow evaporation of a solution of isolated Ga–HBEDmaterial
in water and acetonitrile provided crystals suitable for X-ray
diﬀraction (Table S1†). The selected crystal contained the
neutral [Ga(HBED)(H2O)] complex crystallised with a molecule
of acetonitrile, and the unit cell contained four symmetry-
related equivalents of [Ga(HBED)(H2O)]$CH3CN, including
both D and L enantiomers of the Ga3+ complex. In
[Ga(HBED)(H2O)], HBED is bound to Ga
3+ in a pentadentate
N2O3 environment, with only one phenolic group coordinated
to Ga3+ (Fig. 6). The non-coordinating phenolic group is
protonated and uncharged. A water molecule occupies the
remaining Ga3+ coordination site to give an octahedral Ga3+
complex in which the two carboxylate groups are coordinated
trans to each other, and the single coordinating phenolic group
and H2O ligand are cis to each other. There is some distortion of
the octahedral environment. N–Ga–O bond angles of the ve-
membered chelate rings, formed by the coordinating carbox-
ylate and amine ligands, are signicantly smaller (81.73 and
82.30) than other bond angles about the metal centre (Table
S2†), likely owing to the steric strain in the ligand.
Elemental analysis of the isolated crystalline material indi-
cated that the bulk crystalline material has the same elemental
(C, H, N) composition as the single crystal used to acquire X-ray
diﬀraction data (see Experimental section).
Similar geometric arrangements of the HBED ligand have
been observed for HBED complexes of Ti4+ and Fe3+, although
in these structures, both phenolic groups are coordinated to the
metal centre.67,68 In hexadentate [Ti(HBED)] and [Fe(HBED)],
the two carboxylate groups are trans to each other, and the two
phenolic groups are cis to each other. The metal–HBED ligand
bond lengths in these octahedral complexes are similar to cor-
responding metal–HBED ligand bond lengths of
[Ga(HBED)(H2O)].
HPLC chromatograms of solutions of isolated
[Ga(HBED)(H2O)]$CH3CN gave the same peak shapes as previ-
ously observed (Fig. S4†).
Competition studies
Competition studies36 were undertaken, in which two chelators
were allowed to compete for 68Ga3+ binding, at diﬀerent
temperatures (90 C and 25 C) and diﬀerent pH conditions (pH
3.5 and 6.5). Generator eluate containing 68Ga3+ was added to
solutions containing equimolar concentrations of two chela-
tors. The concentration of each chelator was 500 mM. At this
concentration, the chelators were in large excess over 68Ga3+ and
the above iTLC studies demonstrated that RCYs for every
chelator were near-quantitative. Aer 40 min reaction (to allow
for equilibration), solutions were analysed by reverse phase
HPLC (for example, Fig. 7). Radio-chromatographic signals for
each 68Ga species were integrated, and results summarised as
a percentage of total radioactivity (Tables 3 and 4).
Relative labelling eﬃciency among DOTA, NOTA, NOTP and
TRAP was not compared, as their complexes could not be
adequately separated from each other by HPLC or iTLC. 68Ga
radiolabelled complexes of HBED, DFO and THP showed
distinct retention times under the HPLC conditions employed,
and labelling eﬃciencies of these chelators could be compared
with each other and with each of DOTA, NOTA, NOTP and TRAP.
These competitive comparisons were repeated at pH 3.5 and
6.5, and 25 and 90 C, except for those involving DFO at 90 C.
Under all conditions, THP “competed” most eﬀectively for
68Ga3+ in comparison with all other chelators (Fig. S9†). In each
competition study involving THP at 25 C, RCY of [68Ga(THP)]
was in the range 92–100%. At 90 C, the proportion of 68Ga3+
complexed by the three triazacyclononane (tacn) derivatives
(NOTA, NOTP and TRAP) in competition with THP was signi-
cantly higher than at 25 C, although RCYs of [68Ga(THP)] still
exceeded 60% in these reactions. This suggests that, to some
extent, these 68Ga reaction products at 25 C are a result of
kinetic preferences.
For competition reactions between THP and DOTA, and
between THP and HBED, RCYs of [68Ga(THP)] were 100% under
all conditions.
The three tacn derivatives competed favourably for 68Ga3+ in
reactions with either HBED or DFO (Fig. S10 and S11†). Indeed
in all such competitive reactions, RCYs of 68Ga with either
Fig. 4 (a) Radiochromatogramof [68Ga(HBED)] (prepared at 90 C); (b)
UV chromatogram of [Ga(HBED)]; (c) extracted ion chromatogram of
isolated [Ga(HBED)] (m/z of monoisotopic signal ¼ 455.07); inset
positive ion MS spectrum of {[Ga(HBED)] + 2H+}: [Ga(C20H22N2O6)]
+.
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NOTA, NOTP or TRAP exceeded 55%. Generally, of the three
tacn derivatives, radiochemical yields of [68Ga(NOTP)] were
highest across all competition studies.
Under the tested conditions, HBED “outcompeted” only
DOTA and DFO (Fig. S9 and S10†). At 25 C under both pH
conditions, DFO “outcompeted” only DOTA (Fig. S9–S11†).
Compared to all other chelators and under all tested conditions,
DOTA was least able to compete for 68Ga3+ complexation.
There were no remarkable diﬀerences between competition
studies undertaken at pH 3.5 and pH 6.5, except in the case of
reactions of 68Ga3+ with HBED and TRAP (Fig. S10†). At pH 3.5,
all 68Ga3+ was bound to the TRAP chelator, whereas at pH 6.5,
only 60–80% of added 68Ga3+ was bound to TRAP (depending on
the temperature).
Discussion
There is a prevailing notion in the radiochemical literature,
based largely on knowledge of the pH-dependence of the
hydrolytic behaviour of the Ga3+ aqua ion in forming relatively
insoluble hydroxides, that 68/67Ga3+ chelation is most eﬀective
at pH 5 or lower. Most reactions that assess 68/67Ga complexa-
tion are undertaken at low pH values. Our results demonstrate
that for 68Ga-radiolabelling of NOTA, NOTP, TRAP, HBED, DFO
and THP at 25 C under these specic reaction conditions, RCYs
at pH 6.5 are equal to or greater than RCYs achieved at pH 3.5.
Many reported 68Ga radiolabelling experiments have been
conducted at temperatures greater than 50 C. Our results
demonstrate that for the majority of chelators, heating the
reaction does not signicantly increase RCY. The exceptions to
this are reactions of 68Ga3+ with DOTA at both pH 3.5 and pH
6.5, and THP at pH 3.5. In our hands, heating and low pH
conditions are only favourable in the case of DOTA – the
chelator that is currently used the most for clinical 68Ga
biomolecule labelling. Even under low pH and high tempera-
ture conditions, near-quantitative RCYs for DOTA labelling
(greater than 95%) were only achieved at concentrations of 50
mM and above. In these studies, in which low amounts of 68Ga
were used, this corresponded to maximum specic activities of
20–40 MBq mmol1.
Fig. 5 Regions from (a) 13C{1H} NMR spectra of HBED and [Ga(HBED)],
and (b) 71Ga NMR spectrum of [Ga(HBED)] (60% D2O/40% CD3CN). In
the 13C{1H} NMR spectrum of HBED, three CH2 resonances, one COH
resonance and one COOH resonance are detected, but upon coordi-
nation to Ga3+, an increase in the number of signals is observed. A
residual methanol signal is marked (x). In the 71Ga NMR spectrum of
[Ga(HBED)], a broad, asymmetric peak is observed, distinct from that of
unchelated [Ga(H2O)6]
3+.
Fig. 6 ORTEP representation of [Ga(HBED)(H2O)]$CH3CN. Ellipsoids
are at the 50% probability level. Hydrogen atoms (with the exception of
the proton of the non-coordinating phenolic group) and solvent
molecules are omitted for clarity.
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In contrast, near-quantitative RCYs were achieved for THP
and DFO at pH 6.5 and 25 C, at chelator concentrations as low
as 500 nM, and in aqueous solutions (ammonium acetate
solution) that are physiologically compatible. This corre-
sponded to specic activities of approximately 2–4 GBq mmol1.
For reactions that achieved near quantitative RCYs, the
maximum specic activity for [68Ga(THP)] and [68Ga(DFO)]
(under mild conditions) was two orders of magnitude higher
than that achieved for [68Ga(DOTA)] (under low pH and high
temperature conditions). High radiochemical yields (>80%)
were achieved for NOTP and HBED under the same mild 68Ga-
labelling conditions. Identifying chelators such as these, that
enable reproducible and near-quantitative 68Ga biomolecular
labelling under low chelator concentration, mild conditions
and in physiologically compatible solutions will facilitate (i)
one-step, kit-based radiosynthesis of 68Ga radiopharmaceuti-
cals; and (ii) 68Ga radiolabelling of small proteins (<50 kDa).
Proteins that accumulate at target tissue and clear circulation in
less than four hours (including engineered antibody derivatives
and recombinant proteins) have utility in imaging in vivo
receptor expression,47,69–71 but many are likely to be sensitive to
extremes of pH and temperature.
67Ga-labelled DFO–protein conjugates have previously
demonstrated in vivo and in vitro instability, with DFO releasing
67Ga3+ (between 20–60% dissociation of 67Ga3+ to serum
proteins over three days in solutions containing serum
proteins).28 This is likely a result of kinetic instability of the
[Ga(DFO)] complex, leading to transmetallation of Ga3+ to
endogenous ligands (proteins, peptides and bone mineral) in
vivo and in vitro. However, the shorter half-life of 68Ga renders
prolonged in vivo stability unnecessary. As DFO complexes
68Ga3+ in near quantitative yields under mild conditions at low
concentrations, DFO is possibly very useful for molecular
imaging with 68Ga.72
At pH 6.5 and 25 C, NOTP is more eﬃcient at chelating
68Ga3+ than either of the other tacn derivatives, NOTA and
TRAP, and the radiochemical yield for [68Ga(NOTP)] is greater
than 95% at chelator concentrations of 5 mM. This corre-
sponded to specic activities of 200–400 MBq mmol1. NOTP is
Fig. 7 Exemplar HPLC radiochromatograms from competition
studies: (A) [68Ga(NOTP)] standard; (B) [68Ga(THP)] standard; reaction
solutions (pH 6.5) containing equimolar concentrations (500 mM) of
THP and NOTP with 68Ga3+ eluate at (C) 25 C and (D) 90 C. Radio-
chromatograms from competition studies are included in ESI, Fig. S9–
S11.†
Table 3 68Ga competition studies at pH 3.5: equimolar solutions of
HBED, THP or DFOwith either DOTA, NOTA, NOTP, TRAP, HBED, THP
or DFO, were reacted with 68Ga3+. The RCYs of [68Ga(HBED)],
[68Ga(THP)] and [68Ga(DFO)] for each of these reactions are given in
the below table
25 C 90 C
HBED THP DFO HBED THP
DOTA 99% HBED 100% THP 100% DFO 96% HBED 100% THP
NOTA 43% HBED 97% THP 38% DFO 32% HBED 79% THP
NOTP 0% HBED 94% THP 24% DFO 0% HBED 64% THP
TRAP 0% HBED 100% THP 30% DFO 0% HBED 82% THP
HBED — 100% THP 17% DFO — 100% THP
THP 0% HBED — 0% DFO 0% HBED —
Table 4 68Ga competition studies at pH 6.5: equimolar solutions of
HBED, THP or DFOwith either DOTA, NOTA, NOTP, TRAP, HBED, THP
or DFO, were reacted with 68Ga3+. The RCYs of [68Ga(HBED)],
[68Ga(THP)] and [68Ga(DFO)] for each of these reactions are given in
the below table
25 C 90 C
HBED THP DFO HBED THP
DOTA 99% HBED 100% THP 100% DFO 96% HBED 100% THP
NOTA 41% HBED 99% THP 33% DFO 38% HBED 87% THP
NOTP 0% HBED 92% THP 26% DFO 0% HBED 77% THP
TRAP 38% HBED 100% THP 25% DFO 20% HBED 88% THP
HBED — 100% THP 18% DFO — 100% THP
THP 0% HBED — 0% DFO 0% HBED —
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also potentially very useful for 68Ga biomolecule labelling under
mild conditions. Additionally, out of all chelators except THP,
NOTP competes most eﬀectively for 68Ga3+ in competition
reactions. Whilst other tacn derivatives, TRAP and NOTA, have
been extensively studied for 68Ga biomolecule labelling, 68Ga
bioconjugates of NOTP have not been reported. Reassessment
of its utility would be timely.
At pH 6.5 at both high and low temperatures, HBED eﬃciently
chelates 68Ga3+, achieving 85% RCY at concentrations as low as
500 nM. LC-MS and NMR data for HBED complexes of 68/natGa3+
indicate that under the analytical conditions described here,
more than one chemically distinct species exists in solution. It is
possible that neutral pentadentate complexes, such as
[Ga(HBED)(H2O)] observed by single crystal X-ray diﬀraction
(Fig. 6), exist within this population of Ga–HBED species. In light
of the geometric arrangement of donor atoms in crystals of
[Ga(HBED)(H2O)]$CH3CN, and existing data on hexadentate
HBED complexes of Ti4+ and Fe3+,67,68 we postulate that hex-
adentate [Ga(HBED)]-2 (Fig. 3) is also present in solution.
The analytical chromatographic and spectroscopic condi-
tions used in this study (and in prior studies10,65) do not mimic
physiological conditions. Nonetheless, the data demonstrate
the intricate speciation of HBED complexes of Ga3+. Detailed
speciation studies under physiologically-relevant conditions are
required. The log Ka values for phenolic protons of HBED are
12.6 and 11.0,52 and it is possible that the diﬀerent species of
Ga–HBED (and indeed Ga–HBED–PSMA) arise from uxionality
in the coordination/dissociation of the phenolic oxygen ligands.
It is likely that in solutions at higher pH values than those
studied here, Ga–HBED exists exclusively as a hexadentate
complex. It is also possible that a hexadentate complex would
be observed in the solid state, if proton counter ions were
substituted for other cations.
Competition studies, in which an equimolar solution of two
chelators was reacted with 68Ga3+, indicated that out of all tested
chelators and under all tested conditions (which were not
concentration-limited), THP competed most eﬀectively for Ga3+.
These data, alongside THP radiolabelling studies that demon-
strate very high 68Ga radiolabelling eﬃciency, point to THP
possessing ideal properties for rapid radiolabelling under mild
conditions.33–35,37,39 It is likely that other chelators that have
demonstrated suitable properties for kit-based radiolabelling,
such as DEDPA,30–32 FSC,27 and DATA,24,25 which we have not
tested in this study, possess similar properties. Such properties
will enable rapid, one-step kit-based syntheses of 68Ga-
biomolecules for molecular PET imaging without the require-
ment for complex automated equipment or specialist radio-
chemistry expertise. This will be key to providing many more
hospitals and patients with access to 68Ga radiopharmaceuticals.
Whilst thermodynamic and kinetic studies can predict the
utility of a chelator for binding very low concentrations of metal
ions, it is diﬃcult to compile all necessary data to reliably model
the complex reaction matrix of radiolabelling solutions. These
solutions contain adventitious metal ions present in concen-
trations exceeding that of 68Ga, and buﬀer/salt components,
which can coordinate both Ga3+ and other metal ions, and
determine metal ion speciation and reactivity. The simple
radiolabelling experiments that we have described here enable
identication of suitable and eﬃcient chelators for kit-based
68Ga3+ radiolabelling, in a reaction matrix typical of radio-
pharmaceutical formulations.
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